Studies in patients of NSCLC treated with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors), including Iressa or Tarceva, have shown that acquired resistance to EGFR-TKIs due to c-MET over-expression in approximately 20% population [7], which cause PI3K/Akt pathway activity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.